Clinical Trial Update: Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2) [Phase 3]

View source ↗

Summary

Phase 3 CONNEX-2 study evaluating Iclepertin for cognition and functional capacity in schizophrenia has completed, with results posted on December 12, 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Iclepertin

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2025-12-12